India Pharma Outlook Team | Thursday, 23 April 2026
Shares of Alembic Pharmaceuticals edged up 1.09 percent to Rs 772.55 after the company revealed plans to strengthen its global footprint with a new subsidiary in Southeast Asia.
The move signals Alembic Pharmaceuticals’ continued push into international markets as it looks to tap growth opportunities beyond India.
The company has incorporated Alembic Lifesciences Philippines Inc., a new entity that will focus on building its presence in the region.
The subsidiary will handle the promotion, sale, and distribution of pharmaceutical products while also exploring fresh business opportunities across the Philippines. This expansion aligns with the company’s broader strategy of scaling operations in high-potential overseas markets.
Also Read: The Future of MedTech in India: Meeting Tier-2 and Tier-3 Needs
Alembic Pharmaceuticals will retain a dominant 99.99 percent stake in the newly formed unit, ensuring full control over its operations and direction. The subsidiary has been set up with an authorized share capital of 12 million Philippine pesos, divided into 1.2 million shares of 10 pesos each. This structure gives the company a solid base to begin operations and gradually expand its reach.
A vertically integrated player, Alembic Pharmaceuticals is known for its strong research and development capabilities and a wide portfolio of generic drugs sold across global markets. Despite steady growth in revenue, the company’s recent financial performance showed some pressure on profitability. For the third quarter of FY26, consolidated net profit slipped 3.9 percent to Rs 132.97 crore. However, net sales rose 10.8 percent year-on-year to Rs 1,876.31 crore, reflecting healthy demand.
The Philippines entry is expected to support long-term growth, even as Alembic Pharmaceuticals balances expansion with margin challenges in the near term.
.jpg)
.jpg)
